Mother to Child Transmission of HIV
Conditions
Keywords
HIV, Pregnancy, Prevention of mother-to-child transmission
Brief summary
The purpose of this study is to provide a surveillance system to monitor changes in the rate of mother to child HIV transmission and preventive practices in France and especially to identify the occurrence of toxicity in children exposed perinatally to antiretroviral drugs.
Detailed description
The goal of the CO11 national cohort is to provide with CO1 a wider surveillance system to monitor changes in the rate of mother to child transmission and preventive practices in France and especially to identify the occurrence of toxicity in children exposed perinatally to antiretroviral drugs. The CO11 EPF enrolle HIV infected women who delivery in maternity generally smaller than CO1 maternity (15 sites in Paris area, 35 in mainland France and 4 in the DOM). Maternal clinical, biological and therapeutic data before and during pregnancy were collected at delivery, with simplified questionnaires. The children are examined clinically and biologically at birth, 6, 12 and 24 months.
Interventions
None listed
Sponsors
ANRS, Emerging Infectious Diseases
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* pregnant women \>= 18 years * infected with HIV1 and/or HIV2
Exclusion criteria
* guardianship or judicial or administrative detention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of PMTCT strategies by measuring rate of mother to child transmission of HIV | At birth up to 24 months | Number of infected children (HIV RNA \>50c/mL or Positive serology) reported on the total number of children |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immuno-virological response during pregnancy | At inclusion up to childbirth | HIV ARN \<50c/mL, CD4 cells count\>500 cells/mL |
| Tolerance and toxicity of different kind of MTCT prophylaxis during pregnancy | At inclusion up to childbirth | incidence of pathologies during pregnancy |
| Impact of different kind of MTCT prophylaxis on childbirth | At delivery | Childbirth mode (Number of emergency Caesarean section, Number of planned caesarean section) |
| Impact of different kind of MTCT prophylaxis during pregnancy on uninfected children | At childbirth, 1 month, 3 months, 6 months, 12 months and 18-24 months | Clinical abnormalities (occurrence of adverse events) |
Countries
France, French Guiana, Guadeloupe, Martinique
Contacts
Primary ContactJosiane WARSZAWSKI
Backup ContactMaud BROSSARD
Outcome results
None listed